Dare Bioscience (DARE) announced it will host a live webinar on Monday, November 17, 2025, on the DARE to PLAY difference with leading sexual health and menopause clinicians Dr. Sheryl Kingsberg and Dr. Jim Simon. DARE to PLAY Sildenafil Cream is a first-of-its-kind topical sildenafil formulation designed specifically for women to enhance genital blood flow and arousal response. The company said, “Its anticipated upcoming commercial availability through a 503B outsourcing facility will mark the first time a topical sildenafil formulation manufactured in accordance with cGMP requirements and supported by clinical data will be accessible to healthcare providers and their patients.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Is DARE a Buy, Before Earnings?
- Dare Bioscience to receive up to $300,000 to conduct landscape review
- Daré Bioscience Advances Progesterone Delivery Study for Preterm Birth Prevention
- Daré Bioscience’s Ovaprene Study: A New Era in Contraceptive Innovation
- Dare Bioscience receives $4M non-dilutive grant installment